Mast cell tryptase β as a target in allergic inflammation: An evolving story

Current Pharmaceutical Design

Volumn 13, Issue 3, 2007, Pages 313-332

  Sommerhoff, C P ^a   Schaschke, N ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

Author keywords

Allergic inflammation; Asthma; Mast cells; Tryptase inhibitors; Tryptases

Indexed keywords

1,2 BENZISOTHIAZOL 3 ONE 1,1 DIOXIDE DERIVATIVE; 1,2,5 THIADIAZOLIDIN 3 ONE 1,1 DIOXIDE DERIVATIVE; 4 AMIDINO BENZOIC ACID DERIVATIVE; 4 AMIDINOPHENYLPYRUVIC ACID; 4 CARBOXY 2 AZETIDINONE DERIVATIVE; 4',6 DIAMIDINO 2 PHENYLINDOLE; AZETIDINONE DERIVATIVE; BENZOIC ACID DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BIOCHEMICAL MARKER; BMS 262084; BMS 363131; CYCLOPEPTIDE; GABEXATE MESILATE; ISOENZYME; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; NAFAMSTAT MESILATE; PYRUVIC ACID DERIVATIVE; RWJ 56423; SERINE PROTEINASE; SYNTHETIC PEPTIDE; TETRAMER; THIAZOLIDINE DERIVATIVE; TRYPTASE; TRYPTASE ALPHA; TRYPTASE BETA; TRYPTASE DELTA; TRYPTASE GAMMA; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ASTHMA; ALLERGIC DISEASE; BASOPHIL; BINDING AFFINITY; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATORY DISEASE; MAST CELL; NONHUMAN; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BINDING SITES; DRUG DESIGN; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; INFLAMMATION; MAST CELLS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRYPTASES;

EID: 33846160570     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313579     Document Type: Review

References (172)

1. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, et al. The human mast cell: functions in physiology and disease. Front Biosci 2001; 6: D1109-27.
2. Schwartz LB. Analysis of MCT and MCTC mast cells in tissue. Methods Mol Biol 2005; 315: 53-62.
3. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004; 59: 695-703.
4. Bachelet I, Munitz A, Levi-Schaffer F. Tryptase as an inflammatory marker in allergic disease and asthma. Expert Rev Clin Immunol 2005; 1: 63-73.
5. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11; quiz 2.
6. Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol 2005; 114: 41-51.
7. Caughey GH. Tryptases. In: Barrett AJ, Rawlings ND, Woessner JF, Eds., Handbook of Proteolytic Enzymes. 2 ed. London, Elsevier 2004; 1535-43.
8. Fiorucci L, Ascoli F. Mast cell tryptase, a still enigmatic enzyme. Cell Mol Life Sci 2004; 61: 1278-95.
9. Caughey GH. New developments in the genetics and activation of mast cell proteases. Mol Immunol 2002; 38: 1353-7.
10. Pallaoro M, Fejzo MS, Shayesteh L, Blount JL, Caughey GH. Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3. J Biol Chem 1999; 274: 3355-62.
11. Wong GW, Tang Y, Feyfant E, Sali A, Li L, Li Y, et al. Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension. J Biol Chem 1999; 274: 30784-93.
12. Caughey GH, Raymond WW, Blount JL, Hau LW, Pallaoro M, Wolters PJ, et al. Characterization of human gamma-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families. J Immunol 2000; 164: 6566-75.
13. Soto D, Malmsten C, Blount JL, Muilenburg DJ, Caughey GH. Genetic deficiency of human mast cell alpha-tryptase. Clin Exp Allergy 2002; 32: 1000-6.
14. Guida M, Riedy M, Lee D, Hall J. Characterization of two highly polymorphic human tryptase loci and comparison with a newly discovered monkey tryptase ortholog. Pharmacogenetics 2000; 10: 389-96.
15. Harris JL, Niles A, Burdick K, Maffitt M, Backes BJ, Ellman JA, et al. Definition of the extended substrate specificity determinants for beta-tryptases I and II. J Biol Chem 2001; 276: 34941-7.
16. Sakai K, Ren S, Schwartz LB. A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I. J Clin Invest 1996; 97: 988-95.
17. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 2001; 276: 18551-6.
18. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J Immunol 1992; 148: 2475-82.
19. Lindstedt KA, Kokkonen JO, Kovanen PT. Regulation of the activity of secreted human lung mast cell tryptase by mast cell proteoglycans. Biochim Biophys Acta 1998; 1425: 617-27.
20. Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J Biol Chem 1986; 261: 7372-9.
21. Addington AK, Johnson DA. Inactivation of human lung tryptase: evidence for a re-activatable tetrameric intermediate and active monomers. Biochemistry 1996; 35: 13511-8.
22. Ren S, Sakai K, Schwartz LB. Regulation of human mast cell beta-tryptase: conversion of inactive monomer to active tetramer at acid pH. J Immunol 1998; 160: 4561-9.
23. Fajardo I, Pejler G. Formation of active monomers from tetrameric human beta-tryptase. Biochem J 2003; 369: 603-10.
24. Fukuoka Y, Schwartz LB. Human beta-tryptase: detection and characterization of the active monomer and prevention of tetramer reconstitution by protease inhibitors. Biochemistry 2004; 43: 10757-64.
25. Hallgren J, Lindahl S, Pejler G. Structural requirements and mechanism for heparin-dependent activation and tetramerization of human betaI- and betaII-tryptase. J Mol Biol 2005; 345: 129-39.
26. Strik MC, Wolbink A, Wouters D, Bladergroen BA, Verlaan AR, van Houdt IS, et al. Intracellular serpin SERPINB6 (PI6) is abundantly expressed by human mast cells and forms complexes with beta-tryptase monomers. Blood 2004; 103: 2710-7.
27. Schwartz LB, Min HK, Ren S, Xia HZ, Hu J, Zhao W, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003; 170: 5667-73.
28. Huang C, Li L, Krilis SA, Chanasyk K, Tang Y, Li Z, et al. Human tryptases alpha and beta/II are functionally distinct due, in part, to a single amino acid difference in one of the surface loops that forms the substrate-binding cleft. J Biol Chem 1999; 274: 19670-6.
29. Selwood T, Wang ZM, McCaslin DR, Schechter NM. Diverse stability and catalytic properties of human tryptase alpha and beta isoforms are mediated by residue differences at the S1 pocket. Biochemistry 2002; 41: 3329-40.
30. Gabrijelcic-Geiger D, Schaschke N, Streicher S, Zettl F, Mentele R, Sommerhoff CP. Human mast cell tryptase alpha/beta-heterotetramers. Submitted.
31. Wang HW, McNeil HP, Husain A, Liu K, Tedla N, Thomas PS, et al. Delta tryptase is expressed in multiple human tissues, and a recombinant form has proteolytic activity. J Immunol 2002; 169: 5145-52.
32. Min HK, Kambe N, Schwartz LB. Human mouse mast cell protease 7-like tryptase genes are pseudogenes. J Allergy Clin Immunol 2001; 107: 315-21.
33. Wong GW, Foster PS, Yasuda S, Qi JC, Mahalingam S, Mellor EA, et al. Biochemical and functional characterization of human transmembrane tryptase (TMT)/tryptase gamma. TMT is an exocytosed mast cell protease that induces airway hyperresponsiveness in vivo via an interleukin-13/ interleukin-4 receptor alpha/signal transducer and activator of transcription (STAT) 6-dependent pathway. J Biol Chem 2002; 277: 41906-15.
34. Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, et al. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 1998; 392: 306-11.
35. Sommerhoff CP, Bode W, Pereira PJ, Stubbs MT, Sturzebecher J, Piechottka GP, et al. The structure of the human betaII-tryptase tetramer: fo(u)r better or worse. Proc Natl Acad Sci USA 1999; 96: 10984-91.
36. Sommerhoff CP, Bode W, Matschiner G, Bergner A, Fritz H. The human mast cell tryptase tetramer: a fascinating riddle solved by structure. Biochim Biophys Acta 2000; 1477: 75-89.
37. Marquardt U, Zettl F, Huber R, Bode W, Sommerhoff C. The crystal structure of human alpha 1-tryptase reveals a blocked substrate-binding region. J Mol Biol 2002; 321: 491-502.
38. Huang C, De Sanctis GT, O'Brien PJ, Mizgerd JP, Friend DS, Drazen JM, et al. Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung. J Biol Chem 2001; 276: 26276-84.
39. Furlong ST, Mauger RC, Strimpler AM, Liu YP, Morris FX, Edwards PD. Synthesis and physical characterization of a P1 arginine combinatorial library, and its application to the determination of the substrate specificity of serine peptidases. Bioorg Med Chem 2002; 10: 3637-47.
40. Gosalia DN, Salisbury CM, Ellman JA, Diamond SL. High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays. Mol Cell Proteomics 2005; 4: 626-36.
41. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988; 244: 133-7.
42. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1990; 3: 27-32.
43. Walls AF, Brain SD, Desai A, Jose PJ, Hawkings E, Church MK, et al. Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. Biochem Pharmacol 1992; 43: 1243-8.
44. Imamura T, Dubin A, Moore W, Tanaka R, Travis J. Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 1996; 74: 861-70.
45. Kozik A, Moore RB, Potempa J, Imamura T, Rapala-Kozik M, Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem 1998; 273: 33224-9.
46. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657-62.
47. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994; 269: 9416-9.
48. Lee M, Sommerhoff CP, von Eckardstein A, Zettl F, Fritz H, Kovanen PT. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 2086-91.
49. Maier M, Spragg J, Schwartz LB. Inactivation of human high molecular weight kininogen by human mast cell tryptase. J Immunol 1983; 130: 2352-6.
50. Schwartz LB, Bradford TR, Littman BH, Wintroub BU. The fibrinogenolytic activity of purified tryptase from human lung mast cells. J Immunol 1985; 135: 2762-7.
51. Thomas VA, Wheeless CJ, Stack MS, Johnson DA. Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 1998; 37: 2291-8.
52. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem 1992; 50: 337-49.
53. Kaminska R, Helisalmi P, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Focal dermal-epidermal separation and fibronectin cleavage in basement membrane by human mast cell tryptase. J Invest Dermatol 1999; 113: 567-73.
54. Fajardo I, Pejler G. Human mast cell beta-tryptase is a gelatinase. J Immunol 2003; 171; 1493-9.
55. Kielty CM, Lees M, Shuttleworth CA, Woolley D. Catabolism of intact type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem Biophys Res Commun 1993; 191: 1230-6.
56. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 2004; 114: 997-1008; quiz 9.
57. McGuire JJ. Proteinase-activated receptor 2 (PAR2): a challenging new target for treatment of vascular diseases. Curr Pharm Des 2004; 10: 2769-78.
58. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005; 26: 1-43.
59. Brown JK, Jones CA, Rooney LA, Caughey GH, Hall IP. Tryptase's potent mitogenic effects in human airway smooth muscle cells are via nonproteolytic actions. Am J Physiol Lung Cell Mol Physiol 2002; 282: L197-206.
60. Vliagoftis H, Lacy P, Luy B, Adamko D, Hollenberg M, Befus D, et al. Mast cell tryptase activates peripheral blood eosinophils to release granule-associated enzymes. Int Arch Allergy Immunol 2004; 135: 196-204.
61. Brown JK, Hollenberg MD, Jones CA. Tryptase activates phosphatidylinositol 3-kinases proteolytically independent from proteinase activated receptor-2 in cultured dog airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006; 290: L259-69.
62. Sekizawa K, Caughey GH, Lazarus SC, Gold WM, Nadel JA. Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. J Clin Invest 1989; 83: 175-9.
63. Johnson PR, Ammit AJ, Carlin SM, Armour CL, Caughey GH, Black JL. Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur Respir J 1997; 10: 38-43.
64. Berger P, Compton SJ, Molimard M, Walls AF, N'Guyen C, Marthan R, et al. Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi. Clin Exp Allergy 1999; 29: 804-12.
65. Berger P, Perng DW, Thabrew H, Compton SJ, Cairns JA, McEuen AR, et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 2001; 91: 1372-9.
66. Berger P, Girodet PO, Begueret H, Ousova O, Perng DW, Marthan R, et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J 2003; 17: 2139-41.
67. Woodruff PG, Dolganov GM, Ferrando RE, Donnelly S, Hays SR, Solberg OD, et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004; 169: 1001-6.
68. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346: 1699-705.
69. Berger P, Girodet PO, Manuel Tunon-de-Lara J. Mast cell myositis: a new feature of allergic asthma? Allergy 2005; 60: 1238-40.
70. Franconi GM, Graf PD, Lazarus SC, Nadel JA, Caughey GH. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J Pharmacol Exp Ther 1989; 248: 947-51.
71. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6: 151-8.
72. He S, Walls AF. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur J Pharmacol 1997; 328: 89-97.
73. Greenfeder S, Sehring S, McHugh N, Corboz M, Rivelli M, Anthes JC, et al. Tryptase-induced airway microvascular leakage in guinea pigs: involvement of tachykinins and leukotrienes. Eur J Pharmacol 2001; 419: 261-7.
74. Walls AF, He S, Teran LM, Buckley MG, Jung KS, Holgate ST, et al. Granulocyte recruitment by human mast cell tryptase. Int Arch Allergy Immunol 1995; 107: 372-3.
75. He S, Peng Q, Walls AF. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 1997; 159: 6216-25.
76. Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996; 156: 275-83.
77. Compton SJ, Cairns JA, Holgate ST, Walls AF. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J Immunol 1998; 161: 1939-46.
78. Kinoshita M, Okada M, Hara M, Furukawa Y, Matsumori A. Mast cell tryptase in mast cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 1858-63.
79. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005; 280: 34661-6.
80. Molinari JF, Moore WR, Clark J, Tanaka R, Butterfield JH, Abraham WM. Role of tryptase in immediate cutaneous responses in allergic sheep. J Appl Physiol 1995; 79: 1966-70.
81. Molinari JF, Scuri M, Moore WR, Clark J, Tanaka R, Abraham WM. Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am J Respir Crit Care Med 1996; 154: 649-53.
82. He S, Gaca MD, Walls AF. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther 1998; 286: 289-97.
83. He SH, Xie H, Fu YL. Activation of human tonsil and skin mast cells by agonists of proteinase activated receptor-2. Acta Pharmacol Sin 2005; 26: 568-74.
84. Temkin V, Kantor B, Weg V, Hartman ML, Levi-Schaffer F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol 2002; 169: 2662-9.
85. Shpacovitch VM, Varga G, Strey A, Gunzer M, Mooren F, Buddenkotte J, et al. Agonists of proteinase-activated receptor-2 modulate human neutrophil cytokine secretion, expression of cell adhesion molecules, and migration within 3-D collagen lattices. J Leukoc Biol 2004; 76: 388-98.
86. Guyot N, Zani ML, Berger P, Dallet-Choisy S, Moreau T. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Biol Chem 2005; 386: 391-9.
87. Elrod KC, Moore WR, Abraham WM, Tanaka RD. Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep. Am J Respir Crit Care Med 1997; 156: 375-81.
88. Cregar L, Elrod KC, Putnam D, Moore WR. Neutrophil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase. Arch Biochem Biophys 1999; 366: 125-30.
89. Sommerhoff CP. Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 2001; 164: S52-8.
90. Saito H. Role of mast cell proteases in tissue remodeling. Chem Immunol Allergy 2005; 87: 80-4.
91. Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart FX, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002; 32: 237-46.
92. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-700.
93. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003; 60: 64-9.
94. Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest 1997; 99: 1313-21.
95. Coutts A, Chen G, Stephens N, Hirst S, Douglas D, Eichholtz T, et al. Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen. Am J Physiol Lung Cell Mol Physiol 2001; 280: L999-1008.
96. Forteza RM, Ahmed A, Lee T, Abraham WM. Secretory leukocyte protease inhibitor, but not alpha-1 protease inhibitor, blocks tryptase-induced bronchoconstriction. Pulm Pharmacol Ther 2001; 14: 107-10.
97. De Sanctis GT, Merchant M, Beier DR, Dredge RD, Grobholz JK, Martin TR, et al. Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. Nat Genet 1995; 11: 150-4.
98. Hunt JE, Stevens RL, Austen KF, Zhang J, Xia Z, Ghildyal N. Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse. J Biol Chem 1996; 271: 2851-5.
99. Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, et al. Delayed onset of inflammation in protease-activated receptor-2-deficient mice. J Immunol 2000; 165: 6504-10.
100. Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002; 169: 5315-21.
101. Knight DA, Lim S, Scaffidi AK, Roche N, Chung KF, Stewart GA, et al. Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 2001; 108: 797-803.
102. Alter SC, Kramps JA, Janoff A, Schwartz LB. Interactions of human mast cell tryptase with biological protease inhibitors. Arch Biochem. Biophys 1990; 276: 26-31.
103. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry 2001; 40: 7342-9.
104. Fiorucci L, Erba F, Ascoli F. Histone-tryptase interaction: H2A N-terminal tail removal and inhibitory activity. Arch Biochem Biophys 1997; 347: 229-34.
105. Sommerhoff CP, Söllner C, Mentele R, Piechottka GP, Auerswald EA, Fritz H. A Kazal-type inhibitor of human mast cell tryptase: isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis. Biol Chem Hoppe Seyler 1994; 375: 685-94.
106. Stubbs MT, Morenweiser R, Stürzebecher J, Bauer M, Bode W, Huber R, et al. The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin. Implications for the structure of human mast cell tryptase and its inhibition. J Biol Chem 1997; 272: 19931-7.
107. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 1997; 344: 133-8.
108. Scarpi D, McBride JD, Leatherbarrow RJ. Inhibition of human beta-tryptase by Bowman-Birk inhibitor derived peptides. J Pept Res 2002; 59: 90-3.
109. Scarpi D, McBride JD, Leatherbarrow RJ. Inhibition of human beta-tryptase by Bowman-Birk inhibitor derived peptides: creation of a new tri-functional inhibitor. Bioorg Med Chem 2004; 12: 6045-52.
110. Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, et al. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther 1999; 289: 1007-14.
111. Barrios VE, Middleton SC, Kashem MA, Havill AM, Toombs CF, Wright CD. Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi. Life Sci 1998; 63: 2295-303.
112. Delaria K, Muller D. High-performance liquid chromatographic assay for tryptase based on the hydrolysis of dansyl-vasoactive intestinal peptide. Anal Biochem 1996; 236: 74-81.
113. Stürzebecher J, Prasa D, Sommerhoff CP. Inhibition of human mast cell tryptase by benzamidine derivatives. Biol Chem Hoppe Seyler 1992; 373: 1025-30.
114. Caughey GH, Raymond WW, Bacci E, Lombardy RJ, Tidwell RR. Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases. J Pharmacol Exp Ther 1993; 264: 676-82.
115. Fiorucci L, Erba F, Bolognesi M, Coletta M, Ascoli F. pH dependence of bovine mast cell tryptase catalytic activity and of its inhibition by 4′,6-diamidino-2-phenylindole. FEBS Lett 1997; 408: 85-8.
116. Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des 1998; 4: 381-96.
117. Gangloff AR. Tryptase inhibitors in the treatment of pulmonary diseases. Curr Opin Investig Drugs 2000; 1: 79-85.
118. Newhouse BJ. Tryptase inhibitors - review of the recent patent literature. IDrugs 2002; 5: 682-8.
119. Cairns JA. Inhibitors of mast cell tryptase beta as therapeutics for the treatment of asthma and inflammatory disorders. Pulm Pharmacol Ther 2005; 18: 55-66.
120. Clark JM, Abraham WM, Fishman CE, Forteza R, Ahmed A, Cortes A, et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995; 152: 2076-83.
121. Clark JM, Moore WR, Tanaka RD. Tryptase inhibitors: a new class of antiinflammatory drugs. Drugs of the Future 1996; 21: 811-6.
122. Costanzo MJ, Yabut SC, Almond HR Jr, Andrade-Gordon P, Corcoran TW, De Garavilla L, et al. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone. J Med Chem 2003; 46: 3865-76.
123. Ogbu CO, Qabar MN, Boatman PD, Urban J, Meara JP, Ferguson MD, et al. Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics. Bioorg Med Chem Lett 1998; 8: 2321-6.
124. Fuchi N, Doi T, Harada T, Urban J, Cao B, Kahn M, et al. The synthesis of beta-strand mimetic templates via regioselective 1,3-dipolar cycloaddition with vinylsulphone. Tetrahedron Lett 2001; 42: 1305-8.
125. Fox MT, Harriott P, Walker B, Stone SR. Identification of potential activators of proteinase-activated receptor-2. FEBS Lett 1997; 417: 267-9.
126. Jackson DS, Fraser SA, Ni LM, Kam CM, Winkler U, Johnson DA, et al. Synthesis and evaluation of diphenyl phosphonate esters as inhibitors of the trypsm-like granzymes A and K and mast cell tryptase. J Med Chem 1998; 41: 2289-301.
127. Ni LM, Powers JC. Synthesis and kinetic studies of an amidine-containing phosphonofluoridate: a novel potent inhibitor of trypsin-like enzymes. Bioorg Med Chem 1998; 6: 1767-73.
128. Murakami Y, Takei M, Shindo K, Kitazume C, Tanaka J, Higa T, et al. Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod 2002; 65: 259-61.
129. Combrink KD, Gulgeze HB, Meanwell NA, Pearce BC, Zulan P, Bisacchi GS, et al. 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase. J Med Chem 1998; 41: 4854-60.
130. Yu KL, Civiello R, Roberts DG, Seiler SM, Meanwell NA. Solid-phase synthesis of benzisothiazolones as serine protease inhibitors. Bioorg Med Chem Lett 1999; 9: 663-6.
131. Wong T, Groutas CS, Mohan S, Lai Z, Alliston KR, Vu N, et al. 1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human tryptase. Arch Biochem Biophys 2005; 436: 1-7.
132. Sutton JC, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, et al. Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 2002; 12: 3229-33.
133. Slusarchyk WA, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, et al. Synthesis of potent and highly selective inhibitors of human tryptase. Bioorg Med Chem Lett 2002; 12: 3235-8.
134. Bisacchi GS, Slusarchyk WA, Bolton SA, Hartl KS, Jacobs G, Mathur A, et al. Synthesis of potent and highly selective nonguanidine azetidinone inhibitors ot human tryptase. Bioorg Med Chem Lett 2004; 14: 2227-31.
135. Sutton JC, Bolton SA, Davis ME, Hartl KS, Jacobson B, Mathur A, et al. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 2004; 14: 2233-9.
136. Qian X, Zheng B, Burke B, Saindane MT, Kronenthal DR. A stereoselective synthesis of BMS-262084, an azetidinone-based tryptase inhibitor. J Org Chem 2002; 67: 3595-600.
137. Zhao G, Bolton SA, Kwon C, Hard KS, Seiler SM, Slusarchyk WA, et al. Synthesis of potent and selective 2-azepanone inhibitors of human tryptase. Bioorg Med Chem Lett 2004; 14: 309-12.
138. Dener JM, Wang VR, Rice KD, Gangloff AR, Kuo EY, Newcomb WS, et al. Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors. Bioorg Med Chem Lett 2001; 11: 2325-30.
139. Erba F, Fiorucci L, Pascarella S, Menegatti E, Ascenzi P, Ascoli F. Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Biochem Pharmacol 2001; 61: 271-6.
140. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003; 92: 420-3.
141. Hopkins C, Neuenschwander K, Scotese A, Jackson S, Nieduzak T, Pauls H, et al. Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation. Bioorg Med Chem Lett 2004; 14: 4819-23.
142. Levell J, Astles P, Eastwood P, Cairns J, Houille O, Aldous S, et al. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase. Bioorg Med Chem 2005; 13: 2859-72.
143. Vaz RJ, Gao Z, Pribish J, Chen X, Levell J, Davis L, et al. Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase. Bioorg Med Chem Lett 2004; 14: 6053-6.
144. Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, et al. Design of potent selective zinc-mediated serine protease inhibitors. Nature 1998; 391: 608-12.
145. Janc JW, Clark JM, Warne RL, Elrod KC, Katz BA, Moore WR. A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by Zinc(II). Biochemistry 2000; 39: 4792-800.
146. Church TJ, Cutshall NS, Gangloff AR, Jenkins TE, Linsell MS, Litvak J, et al. Compounds and compositions for treating diseases associated with serine proteases, particularly tryptase, activity. PCT Int Appl WO 9845275 1998.
147. Mittendorf J, Henning R, Raddatz S, Schlemmer KH, Hiraoka M, Kadono H, et al. New bis-benzimidazoles. PCT Int Appl WO 0020401 2000.
148. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems - Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998; 37: 2754-94.
149. Schaschke N, Dominik A, Matschiner G, Sommerhoff CP. Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors. Bioorg Med Chem Lett 2002; 12: 985-8.
150. Schaschke N, Gabrijelcic-Geiger D, Dominik A, Sommerhoff CP. Affinity chromatography of tryptases: Design, synthesis and characterization of a novel matrix-bound bivalent inhibitor. Chembiochem 2005; 6: 95-103.
151. del Fresno M, Fernandez-Forner D, Miralpeix M, Segarra V, Ryder H, Royo M, et al. Combinatorial approaches towards the discovery of new tryptase inhibitors. Bioorg Med Chem Lett 2005; 15: 1659-64.
152. Ono S, Kuwahara S, Takeuchi M, Sakashita H, Naito Y, Kondo T. Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors. Bioorg Med Chem Lett 1999; 9: 3285-90.
153. Burgess LE, Newhouse BJ, Ibrahim P, Rizzi J, Kashem MA, Hartman A, et al. Potent selective nonpeptidic inhibitors of human lung tryptase. Proc Natl Acad Sci USA 1999; 96: 8348-52.
154. Wright CD, Havill AM, Middleton SC, Kashem MA, Dripps DJ, Abraham WM, et al. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737). Biochem Pharmacol 1999; 58: 1989-96.
155. Rice KD, Gangloff AR, Kuo EY, Dener JM, Wang VR, Lum R, et al. Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors. Bioorg Med Chem Lett 2000; 10: 2357-60.
156. Rice KD, Wang VR, Gangloff AR, Kuo EY, Dener JM, Newcomb WS, et al. Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity. Bioorg Med Chem Lett 2000; 10: 2361-6.
157. Dener JM, Rice KD, Newcomb WS, Wang VR, Young WB, Gangloff AR, et al. Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality. Bioorg Med Chem Lett 2001; 11: 1629-33.
158. Schaschke N, Matschiner G, Zettl F, Marquardt U, Bergner A, Bode W, et al. Bivalent inhibition of human beta-tryptase. Chem Biol 2001; 8: 313-27.
159. Garcia M, del Rio X, Silvestre S, Rubiralta M, Lozoya E, Segarra V, et al. Design, synthesis and biological activity of a targeted library of potential tryptase inhibitors. Org Biomol Chem 2004; 2: 1633-42.
160. Bär T, Stadlwieser J, Ulrich WR, Dominik A, Bundschuh D, Zech K, et al. Tryptase inhibitors. PCT Int Appl WO 0146168 2001.
161. Stadlwieser J, Ulrich WR, Dominik A, Bundschuh D, Eltze M, Zech K, etal. Novel pyranoses. PCT Int Appl WO 0014097 2000.
162. Oh SW, Pae CI, Lee DK, Jones F, Chiang GK, Kim HO, et al. Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol 2002; 168: 1992-2000.
163. Selwood T, Elrod KC, Schechter NM. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem 2003; 384: 1605-11.
164. Sylvin H, Dahlback M, Van Der Ploeg I, Alving K. The tryptase inhibitor APC-366 reduces the acute airway response to allergen in pigs sensitized to Ascaris suum. Clin Exp Allergy 2002; 32: 967-71.
165. Sendo T, Itoh Y, Goromaru T, Sumimura T, Saito M, Aki K, et al. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br J Pharmacol 2003; 138: 959-67.
166. Itoh Y, Sendo T, Oishi R. Physiology and pathophysiology of proteinase-activated receptors (PARs): role of tryptase/PAR-2 in vascular endothelial barrier function. J Pharmacol Sci 2005; 97: 14-9.
167. Krishna MT, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001; 107: 1039-45.
168. Tremaine WJ, Brzezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther 2002; 16: 407-13.
169. Puente XS, Guierrez-Fernandez A, Ordonez GR, Hillier LW, Lopez-Otin C, Comparative genomic analysis of human and chimpanzee proteases. Genomics 2005; 86: 638-47.
170. Gueant-Rodriguez R. M, Romano A, Barbaud A, Brockow K, Gueant J. L. Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des 2006; 12(26): 3359-72.
171. Ventura M. T, Viola M, Calogiuri G, Gaeta F, Pesole O, Romano A. Hypersensitivity reactions to complementary and alternative medicine products. Curr Pharm Des 2006; 12(26): 3393-9.
172. Ventura M. T, Viola M, Gaeta F, Di Leo E, Buquicchio R, Romano A. Hypersensitivity reactions to ophthalmic products. Curr Pharm Des 2006; 12(26): 3401-10.